PURPOSE: The role of complement in ocular autoimmunity was explored in a experimental autoimmune anterior uveitis (EAAU) animal model. METHODS: EAAU was induced in Lewis rats by immunization with bovine melanin-associated antigen. Complement activation in the eye was monitored by Western blot for iC3b. The importance of complement to the development of EAAU was studied by comparing the course of intraocular inflammation in normal Lewis rats (complement-sufficient) with cobra venom factor-treated rats (complement-depleted). Eyes were harvested from both complement-sufficient and complement-depleted rats for mRNA and protein analysis for IFN-gamma, IL-10, and interferon-inducible protein (IP)-10. Intracellular adhesion molecule (ICAM)-1 and leukocyte-endothelial cell adhesion molecule (LECAM)-1 were detected by immunofluorescent staining. OX-42 was used to investigate the importance of iC3b and CR3 interaction in EAAU. RESULTS: There was a correlation between ocular complement activation and disease progression in EAAU. The incidence, duration, and severity of disease were dramatically reduced after active immunization in complement-depleted rats. Complement depletion also completely suppressed adoptive transfer EAAU. The presence of complement was critical for local production of cytokines (IFN-gamma and IL-10), chemokines (IP-10), and adhesion molecules (ICAM-1 and LECAM-1) during EAAU. Furthermore, intraocular complement activation, specifically iC3b production and engagement of complement receptor 3 (CR3), had a significant impact on disease activity in EAAU. CONCLUSIONS: The study provided the novel finding that complement activation plays a central role in the pathogenesis of ocular autoimmunity and may serve as a potential target for therapeutic intervention.
PURPOSE: The role of complement in ocular autoimmunity was explored in a experimental autoimmune anterior uveitis (EAAU) animal model. METHODS: EAAU was induced in Lewis rats by immunization with bovine melanin-associated antigen. Complement activation in the eye was monitored by Western blot for iC3b. The importance of complement to the development of EAAU was studied by comparing the course of intraocular inflammation in normal Lewis rats (complement-sufficient) with cobra venom factor-treated rats (complement-depleted). Eyes were harvested from both complement-sufficient and complement-depleted rats for mRNA and protein analysis for IFN-gamma, IL-10, and interferon-inducible protein (IP)-10. Intracellular adhesion molecule (ICAM)-1 and leukocyte-endothelial cell adhesion molecule (LECAM)-1 were detected by immunofluorescent staining. OX-42 was used to investigate the importance of iC3b and CR3 interaction in EAAU. RESULTS: There was a correlation between ocular complement activation and disease progression in EAAU. The incidence, duration, and severity of disease were dramatically reduced after active immunization in complement-depleted rats. Complement depletion also completely suppressed adoptive transfer EAAU. The presence of complement was critical for local production of cytokines (IFN-gamma and IL-10), chemokines (IP-10), and adhesion molecules (ICAM-1 and LECAM-1) during EAAU. Furthermore, intraocular complement activation, specifically iC3b production and engagement of complement receptor 3 (CR3), had a significant impact on disease activity in EAAU. CONCLUSIONS: The study provided the novel finding that complement activation plays a central role in the pathogenesis of ocular autoimmunity and may serve as a potential target for therapeutic intervention.
Authors: J W Prineas; E E Kwon; E S Cho; L R Sharer; M H Barnett; E L Oleszak; B Hoffman; B P Morgan Journal: Ann Neurol Date: 2001-11 Impact factor: 10.422
Authors: Giang T Tran; Suzanne J Hodgkinson; Nicole Carter; Murray Killingsworth; S Timothy Spicer; Bruce M Hall Journal: J Immunol Date: 2002-05-01 Impact factor: 5.422
Authors: Z Kaya; M Afanasyeva; Y Wang; K M Dohmen; J Schlichting; T Tretter; D Fairweather; V M Holers; N R Rose Journal: Nat Immunol Date: 2001-08 Impact factor: 25.606
Authors: M A Klein; P S Kaeser; P Schwarz; H Weyd; I Xenarios; R M Zinkernagel; M C Carroll; J S Verbeek; M Botto; M J Walport; H Molina; U Kalinke; H Acha-Orbea; A Aguzzi Journal: Nat Med Date: 2001-04 Impact factor: 53.440
Authors: Michael E Stern; Chris S Schaumburg; Karyn F Siemasko; Jianping Gao; Larry A Wheeler; Devin A Grupe; Cintia S De Paiva; Virginia L Calder; Margarita Calonge; Jerry Y Niederkorn; Stephen C Pflugfelder Journal: Invest Ophthalmol Vis Sci Date: 2012-04-24 Impact factor: 4.799
Authors: D A Copland; K Hussain; S Baalasubramanian; T R Hughes; B P Morgan; H Xu; A D Dick; L B Nicholson Journal: Clin Exp Immunol Date: 2009-12-04 Impact factor: 4.330
Authors: Jaime S Rosa; Stacy R Oliver; Masato Mitsuhashi; Rebecca L Flores; Andria M Pontello; Frank P Zaldivar; Pietro R Galassetti Journal: J Investig Med Date: 2008-04 Impact factor: 2.895